Nevertheless, some putative side-effects of using TAX2 as an anti-cancer agent still need to be explored, particularly as TSP-1 interaction with CD47 and/or CD36 is also known to modulate platelet aggregation (Isenberg et al., 2008d). The gene discussed is CD36; the disease is cancer.